DeepMed Research

Chinese Academy of Medical Sciences Peking Union Medical College Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Phase 2

Recruiting

Conditions: Solitary Plasmacytoma

Interventions: Radiation: radiotherapy
Drug: Bortezomib Injection
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2022-02-21

Last Posted Date: 2024-06-05

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 220

Registration Number: NCT05248633

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery

Not Applicable

Active, not recruiting

Conditions: Dexmedetomidine

Interventions: Drug: high dose of dexmedetomidine with sufentanil
Drug: low dose of dexmedetomidine with sufentanil

First Posted Date: 2022-02-21

Last Posted Date: 2024-11-21

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 84

Registration Number: NCT05249153

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

Completed

Conditions: Polypoidal Choroidal Vasculopathy
Conbercept

First Posted Date: 2022-02-08

Last Posted Date: 2022-02-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 500

Registration Number: NCT05229237

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks

Recruiting

Conditions: Anti Phospholipid Syndrome

First Posted Date: 2022-02-08

Last Posted Date: 2024-07-30

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 2000

Registration Number: NCT05230017

Locations: 🇨🇳
Beijing Shunyi Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 15 locations

Study for Rapid Diagnosis of Postoperative Abdominal Infection

Conditions: Postoperative Fever
Postoperative Infection
Abdominal Surgery
Intra-abdominal Infection

First Posted Date: 2022-01-12

Last Posted Date: 2022-09-15

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT05187871

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases

Phase 2

Conditions: Rapid Progressive Interstitial Lung Diseases

Interventions: Drug: Tocilizumab

First Posted Date: 2022-01-06

Last Posted Date: 2022-01-06

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 68

Registration Number: NCT05181397

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma

Phase 2

Conditions: Angioimmunoblastic T-cell Lymphoma

Interventions: Drug: Azacitidine
Drug: Chidamide

First Posted Date: 2022-01-05

Last Posted Date: 2022-01-05

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT05179213

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy

Completed

Conditions: Autoimmune Pancreatitis
Pancreatic Carcinoma
Microflora
Pancreatic Neuroendocrine Tumor

First Posted Date: 2021-12-29

Last Posted Date: 2023-05-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 200

Registration Number: NCT05171517

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617

Not Applicable

Conditions: Renal Cell Carcinoma

Interventions: Drug: 68Ga-PSMA
Drug: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617

First Posted Date: 2021-12-28

Last Posted Date: 2021-12-28

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 40

Registration Number: NCT05170555

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.

Phase 2

Recruiting

Conditions: Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC

Interventions: Drug: Camrelizumab+S-1

First Posted Date: 2021-12-28

Last Posted Date: 2021-12-28

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 42

Registration Number: NCT05170542

Locations: 🇨🇳
Lin Zhao, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy